Castlight health, inc. (CSLT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities:
Net loss

-40,002

-39,706

-51,902

-58,686

-79,920

-85,940

-62,182

-35,004

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,920

6,858

6,613

3,168

2,024

1,354

633

231

Stock-based compensation

15,003

18,132

24,003

21,256

17,830

14,201

2,427

1,311

Amortization and impairment of deferred commissions

10,768

13,105

10,026

5,882

-

-

-

-

Amortization and impairment of deferred professional service costs

5,242

5,268

4,225

-

-

-

-

-

Non-cash operating lease expense

5,315

-

-

-

-

-

-

-

Amortization of deferred commissions

-

-

-

-

3,510

4,092

2,541

10

Amortization and impairment of professional service costs

-

-

-

2,795

-

-

-

-

Release of deferred tax valuation allowance due to business combination

0

0

5,206

0

0

-

-

-

Lease exit and related charges

0

2,634

0

0

-

-

-

-

Change in fair value of contingent consideration liability

0

0

-671

0

0

-

-

-

Accretion and amortization of marketable securities

238

516

83

-481

-1,385

-1,489

-714

-558

Expense related to expiration of SAP warrant

0

0

1,132

0

0

2,639

135

0

Gain on sale of investment in related party

0

0

1,375

0

0

-

-

-

Changes in operating assets and liabilities:
Accounts receivable and other, net

4,581

4,883

2,799

2,278

1,654

6,032

2,703

2,228

Deferred commissions

5,344

5,735

9,888

8,947

-

-

-

-

Deferred professional service costs

1,686

2,735

4,181

4,734

-

-

-

-

Changes in operating assets and liabilities:

-

-

-

-

-7,633

-4,861

-4,959

-3,048

Prepaid expenses and other assets

-102

-178

-1,645

-448

-328

1,895

252

696

Other assets

-

-

-

-

-

-

109

-5

Accounts payable

9,278

5,744

764

-1,035

646

147

868

1,075

Operating lease liabilities

5,726

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-3,760

290

3,493

1,743

-1,158

1,870

2,892

397

Deferred revenue

-10,478

-9,219

-1,943

4,970

-

-

-

-

Accounts payable

-

-

-

-

6,752

15,887

7,268

3,340

Accrued compensation

2,795

-7,966

2,690

-2,034

1,022

2,412

2,544

4,619

Other liabilities, noncurrent

-

-

-

-

-

-

119

105

Net cash used in operating activities

-17,392

-18,551

-23,457

-36,971

-56,868

-54,637

-50,064

-29,325

Investing activities:
Proceeds from sale of investment in related party

0

0

5,500

0

0

-

-

-

Restricted cash

-

-

-

-

-

101

0

129

Investment in related party

-

-

-

-

4,125

0

0

-

Purchase of property and equipment

1,953

2,014

2,544

1,702

5,376

1,860

2,587

458

Purchase of marketable securities

30,589

31,974

62,658

98,184

119,867

230,316

42,288

103,552

Sales of marketable securities

-

-

-

-

5,000

13,000

5,000

19,181

Maturities of marketable securities

25,745

53,210

96,576

146,508

180,111

76,527

72,135

33,196

Business combination, net of cash acquired

0

0

2,264

0

0

-

-

-

Net cash provided by investing activities

-6,797

19,222

34,610

46,622

55,743

-142,548

32,260

-51,504

Financing activities:
Proceeds from exercise of stock options

3,060

4,480

2,356

2,829

-

-

-

-

Proceeds from the exercise of stock options

-

-

-

-

3,944

3,294

864

232

Proceeds from the issuance of common stock and warrants to SAP

-

-

-

17,358

0

-

-

-

Principal payments on long-term debt

1,859

465

0

0

-

-

-

-

Proceeds from initial public offering

-

-

-

-

-

189,943

0

0

Payments of issuance costs related to equity

0

0

731

122

94

3,781

440

0

Proceeds from issuance of convertible preferred stock

-

-

-

-

-

-

-

99,851

Net cash (used in) provided by financing activities

1,201

4,015

1,625

20,065

3,850

189,456

424

100,083

Net (decrease) increase in cash, cash equivalents and restricted cash

-22,988

4,686

12,778

29,716

2,725

-

-

-

Reconciliation of cash, cash equivalents and restricted cash:
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-7,729

-17,380

19,254

Supplemental cash flow information:
Cash paid for interest

188

215

117

-

-

-

-

-

Cash paid during the year for interest

-

-

-

0

0

-

-

-

Non-cash purchase consideration related to acquisition of Jiff

-

-

-

-

0

-

-

-

Non-cash purchase consideration related to acquisition of Jiff

0

0

101,692

0

-

-

-

-

Vesting of early exercised stock options, restricted common stock, and warrants

-

-

-

-

-

321

128

112

Purchase of property and equipment, accrued but not paid

854

93

188

20

165

600

122

581

Right-of-use assets obtained in exchange for new operating lease liabilities, net

1,950

0

0

-

-

-

-

-

Deferred offering costs, accrued but not paid

-

-

-

-

-

94

927

0